Pharmaceutical

Boehringer reinforces interest in NASH with new $2bn deal  

This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.

Jan 3, 2024 - 18:00
Boehringer reinforces interest in NASH with new $2bn deal  
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
Read the original article

Tags:

Previous Article

Opinion: Today’s at-home microbiome testing industry is fraught with snake oil

Next Article

Novartis allies with Voyager to develop gene therapies in $1.3bn deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MSD’s Keytruda and Eisai’s Lenvima fail in Phase III uterine cancer trial

MSD’s Keytruda and Eisai’s Lenvima fail in Phase III ut...

Dec 8, 2023

EC approves Briumvi to treat relapsing forms of multiple sclerosis

EC approves Briumvi to treat relapsing forms of multipl...

Jun 3, 2023

STAT+: The lessons of Aduhelm, Biogen’s Alzheimer’s drug that was not to be

STAT+: The lessons of Aduhelm, Biogen’s Alzheimer’s dru...

Feb 3, 2024